Fiverr International Ltd vs BIO-TECHNE Corp — how do they compare? Fiverr International Ltd trades at $11.8 (market cap $404.45M), while BIO-TECHNE Corp trades at $71.75 (market cap $11.14B). The key difference: BIO-TECHNE Corp is far larger — about 27.5× Fiverr International Ltd's market cap, and BIO-TECHNE Corp pays a 0.45% dividend while Fiverr International Ltd pays none. Which is the better fit depends on your goals.
| FVRR | TECH | |
|---|---|---|
Market Cap | $404.45M | $11.14B |
Sector | Industrials | Health |
52-Week High | $26.67 | $71.48 |
52-Week Low | $9.62 | $43.31 |
Enterprise Value | $135.05M | $11.22B |
Dividend Yield | — | 0.45% |
Signals from Pluang's Aura AI — not financial advice
Fiverr International (FVRR) trades at $11.82, up 6.78% in the last session, showing strong momentum despite recent volatility. The stock exhibits bullish technical signals with moving averages supporting upward movement. Fundamentally, revenue grew to $430.91M in 2025 with improving net margins, while valuation ratios like P/E of 14.61 and P/S of 0.97 suggest potential undervaluation. Recent news highlights Fiverr's upcoming Q2 2026 earnings report on July 29, 2026, amid mixed sentiment from financial media.
The outlook for FVRR hinges on execution of its strategic shift and Q2 earnings performance. Opportunities include attractive valuation multiples and operational cash flow growth, but risks involve declining active buyers and ongoing legal investigations. Analyst consensus leans neutral with 41% buy ratings, reflecting cautious optimism pending clearer business traction.
Bio-Techne (TECH) trades at $71.69, up 0.65% today, near the $73.00 acquisition offer from Merck KGaA announced June 25, 2026. The stock shows bullish technical signals with moving averages supporting upside, though RSI indicates potential overbought conditions. Fundamentally, revenue held at $1.22B in 2025, but net income fell to $73.40M with margin compression. Analysts are split 50/50 buy/hold with a $67.75 consensus target, below the current price, reflecting acquisition uncertainty.
The outlook hinges on the Merck deal closure at $73.00, offering a 1.8% premium from current levels. Risks include shareholder litigation challenging the transaction's fairness and regulatory approval delays. Without the deal, high P/E of 102.12 and declining profitability pose downside risks. The acquisition provides a near-term floor, but execution volatility remains a concern for long-term investors.
Trailing returns across standard periods
Fiverr International Ltd is involved in buying and selling digital services in the same fashion as physical goods on an e-commerce platform. It is set out to design a digital marketplace that is built with a comprehensive SKU-like services catalog and a search, finds, and order process that mirrors a typical e-commerce transaction. The service offerings of the company include Graphics and Design, Digital Marketing, Writing and Translation, and Video and Animation among others.
Read more on FVRR →Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →